Louisiana State Employees Retirement System purchased a new position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Get Rating) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 16,300 shares of the specialty pharmaceutical company’s stock, valued at approximately $261,000.
Other institutional investors have also recently made changes to their positions in the company. Victory Capital Management Inc. boosted its stake in shares of Collegium Pharmaceutical by 21.2% in the second quarter. Victory Capital Management Inc. now owns 132,700 shares of the specialty pharmaceutical company’s stock worth $2,351,000 after acquiring an additional 23,169 shares during the last quarter. Los Angeles Capital Management LLC boosted its stake in shares of Collegium Pharmaceutical by 23.5% in the second quarter. Los Angeles Capital Management LLC now owns 122,898 shares of the specialty pharmaceutical company’s stock worth $2,178,000 after acquiring an additional 23,379 shares during the last quarter. Summit Global Investments boosted its stake in shares of Collegium Pharmaceutical by 103.7% in the second quarter. Summit Global Investments now owns 110,606 shares of the specialty pharmaceutical company’s stock worth $1,960,000 after acquiring an additional 56,306 shares during the last quarter. Monarch Partners Asset Management LLC lifted its position in Collegium Pharmaceutical by 93.9% during the second quarter. Monarch Partners Asset Management LLC now owns 155,301 shares of the specialty pharmaceutical company’s stock worth $2,752,000 after buying an additional 75,226 shares in the last quarter. Finally, Denali Advisors LLC lifted its position in Collegium Pharmaceutical by 76.5% during the second quarter. Denali Advisors LLC now owns 3,000 shares of the specialty pharmaceutical company’s stock worth $53,000 after buying an additional 1,300 shares in the last quarter.
Wall Street Analyst Weigh In
A number of equities analysts recently commented on COLL shares. Needham & Company LLC lifted their price objective on Collegium Pharmaceutical from $34.00 to $35.00 and gave the stock a “buy” rating in a research report on Thursday, January 5th. StockNews.com started coverage on Collegium Pharmaceutical in a research report on Wednesday, October 12th. They set a “hold” rating on the stock. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $33.00.
Insiders Place Their Bets
Collegium Pharmaceutical Price Performance
NASDAQ:COLL opened at $28.74 on Friday. The company has a quick ratio of 0.82, a current ratio of 0.98 and a debt-to-equity ratio of 2.95. The company has a market capitalization of $964.86 million, a P/E ratio of -22.81, a P/E/G ratio of 0.26 and a beta of 0.82. Collegium Pharmaceutical, Inc. has a 52 week low of $14.04 and a 52 week high of $29.78. The stock’s fifty day moving average is $22.77 and its two-hundred day moving average is $19.41.
Collegium Pharmaceutical (NASDAQ:COLL – Get Rating) last released its quarterly earnings data on Thursday, November 3rd. The specialty pharmaceutical company reported $0.96 earnings per share for the quarter, missing analysts’ consensus estimates of $1.04 by ($0.08). Collegium Pharmaceutical had a positive return on equity of 12.66% and a negative net margin of 11.84%. The company had revenue of $127.01 million for the quarter, compared to analyst estimates of $123.65 million. Equities analysts expect that Collegium Pharmaceutical, Inc. will post 3.64 EPS for the current year.
Collegium Pharmaceutical Profile
Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment.
- Get a free copy of the StockNews.com research report on Collegium Pharmaceutical (COLL)
- Deere, Catepillar, PACCAR, Machinery Stocks You Need to Know
- 3 Small-Cap Biopharma Stocks that Could See Big Growth in 2023
- Optimism About Global Demand For Metals Boosts BHP, Other Miners
- Exxon Mobil Expects Earnings and Cash Flow to Grow
- Sorrento Therapeutics, Scilex: 2 Hot Pharma Stocks On the Move
Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.